论文信息 - Human Proinsulin Normalizes Fasting Hyperglycemia in Patients With NIDDM

Human Proinsulin Normalizes Fasting Hyperglycemia in Patients With NIDDM

Human proinsulin (HPI) acutely lowers plasma glucose (PG) with 8% of the potency of insulin on a molar basis (1). Studies have shown the duration of action of HPI is longer than that of insulin, and its ability to suppress hepatic glucose production is 50% greater than its ability to stimulate glucose uptake compared with insulin (2). These data suggest that HPI may have a role in the treatment of patients with non-insulin-dependent diabetes mellitus (NIDDM). We compared the efficacy of HPI versus sulfonylureas in chronically (6 mo) controlling glycemia in patients with NIDDM who had previously not been adequately controlled on sulfonylureas.

H. Lebovitz | R. Pasmantier | S. Hirsch

[1] Classification and Diagnosis of Diabetes Mellitus and Other Categories of Glucose Intolerance , 1979, Diabetes.

[2] J. Olefsky,et al. Mechanisms of insulin resistance in non-insulin-dependent (type II) diabetes. , 1985, The American journal of medicine.

[3] K. Polonsky,et al. The Effects of Biosynthetic Human Proinsulin on Carbohydrate Metabolism , 1984, Diabetes.

[4] R. Henry,et al. Biosynthetic human insulin and proinsulin have additive but not synergistic effects on total body glucose disposal. , 1984, The Journal of clinical endocrinology and metabolism.

[5] H. Lebovitz,et al. Mechanism of action of the second-generation sulfonylurea glipizide. , 1983, The American journal of medicine.

[6] R. Henry,et al. In Vivo Deactivation of Proinsulin Action on Glucose Disposal and Hepatic Glucose Production in Normal Man , 1986, Diabetes.